-
Indian Journal of Nuclear Medicine :... 2022The production of nitrogen-13 (N)-NH by ethanol method using automated synthesizer and accessing the production yield, quality control for clinical application.
AIMS
The production of nitrogen-13 (N)-NH by ethanol method using automated synthesizer and accessing the production yield, quality control for clinical application.
CONTEXT
N, together with F, O, and C, is one of the positron emitters that can be produced on the multi-gigabecquerel scale in biomedical cyclotrons. (N)-ammonia is frequently used for cardiac PET studies. It is widely applied for the evaluation of myocardial perfusion in the clinical assessment of cardiac disorders. Simple, fast, and reliable preparation methods have contributed to the routine application of this tracer. Although only two methods are available, a challenge remains to adopt a more efficient and consistent approach to its production. For clinical application, routine production of this tracer is mandatory in compliance with regulatory guidelines. Being at hospital radiopharmacy it is our responsibility to support the clinical service with uninterrupted production and supply of (N)-NH.
MATERIALS AND METHODS
The chemicals were used commercially available from Sigma Aldrich, India, Ltd., and Fisher Scientific, India, Ltd. (Mumbai, India), Sep-Pak CM cartridges (Waters India, Pvt., Ltd.,). Radio-thin layer chromatography was carried out using aluminum sheets precoated with silica gel 60 F254 (E. Merck, India).
RESULTS
The protocol developed with MPS-100 synthesizer yield (N)-NH95-97% (EOB) with a synthesis time of around 7 min.
CONCLUSIONS
With the installation of HM-18 cyclotron at our hospital, center is capable to produce (N)-NH of good yield and purity through the ethanol method, for mycocardial perfusion studies. Our protocol is simple, reproducible, and robust.
PubMed: 35478690
DOI: 10.4103/ijnm.ijnm_92_21 -
Hormone and Metabolic Research =... Oct 2023The study was to evaluate the effect of radioactive iodine (RAI) treatment application time and clinical, histopathological factors on ablation success in patients with...
The study was to evaluate the effect of radioactive iodine (RAI) treatment application time and clinical, histopathological factors on ablation success in patients with operated papillary thyroid cancer (PTC) in low and intermediate-risk. One hundred sixty-one patients with PTC in the low and intermediate-risk were evaluated. Most patients (89.4%) were in the low-risk, and 10.6% were in the intermediate-risk. When the patients were divided into two groups according to the date of receiving RAI treatment after surgery, those who received early treatment (≤3 months) constituted the majority of the patients (72.7%). Seventeen patients received 1.85 Gigabecquerel (GBq), 119 3.7 GBq, 25 5.55 GBq RAI. Most patients (82%) achieved ablation success after the first RAI treatment. The time interval between surgery and RAI treatment did not affect ablation success. Stimulated Tg level measured on the RAI treatment day was an independent predictive factor for successful ablation (p<0.001). The cut-off value of Tg found to predict ablation failure was 5.86 ng/ml. It was concluded that 5.55 GBq RAI treatment could predict ablation success compared to 1.85 GBq dose (p=0.017). It was concluded that having a T1 tumor may predict treatment success compared to a T2 or T3 tumor (p=0.001, p<0.001, retrospectively). The time interval does not affect ablation success in low and intermediate-risk PTC. The ablation success rate may decrease in patients who receive low-dose RAI and have high Tg levels before treatment. The most crucial factor in achieving ablation success is giving enough doses of RAI to ablate the residual tissue.
Topics: Humans; Thyroid Cancer, Papillary; Iodine Radioisotopes; Thyroid Neoplasms; Retrospective Studies; Carcinoma, Papillary; Thyroidectomy
PubMed: 37267999
DOI: 10.1055/a-2077-7246 -
Frontiers in Radiology 2024Due to a lack of data, there is an ongoing debate regarding the optimal frontline interventional therapy for unresectable hepatocellular carcinoma (HCC). The aim of the...
Outcome of transarterial radioembolization in patients with hepatocellular carcinoma as a first-line interventional therapy and after a previous transarterial chemoembolization.
PURPOSE
Due to a lack of data, there is an ongoing debate regarding the optimal frontline interventional therapy for unresectable hepatocellular carcinoma (HCC). The aim of the study is to compare the results of transarterial radioembolization (TARE) as the first-line therapy and as a subsequent therapy following prior transarterial chemoembolization (TACE) in these patients.
METHODS
A total of 83 patients were evaluated, with 38 patients having undergone at least one TACE session prior to TARE [27 male; mean age 67.2 years; 68.4% stage Barcelona clinic liver cancer (BCLC) B, 31.6% BCLC C]; 45 patients underwent primary TARE (33 male; mean age 69.9 years; 40% BCLC B, 58% BCLC C). Clinical [age, gender, BCLC stage, activity in gigabecquerel (GBq), Child-Pugh status, portal vein thrombosis, tumor volume] and procedural [overall survival (OS), local tumor control (LTC), and progression-free survival (PFS)] data were compared. A regression analysis was performed to evaluate OS, LTC, and PFS.
RESULTS
No differences were found in OS (95% CI: 1.12, = 0.289), LTC (95% CI: 0.003, = 0.95), and PFS (95% CI: 0.4, = 0.525). The regression analysis revealed a relationship between Child-Pugh score (= 0.005), size of HCC lesions (>10 cm) (= 0.022), and OS; neither prior TACE (Child-Pugh B patients; 95% CI: 0.120, = 0.729) nor number of lesions (>10; 95% CI: 2.930, = 0.087) correlated with OS.
CONCLUSION
Prior TACE does not affect the outcome of TARE in unresectable HCC.
PubMed: 38445105
DOI: 10.3389/fradi.2024.1346550